Tirzepatide (injectable and oral disintegrating tablets)
Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The combined action of these hormones provides greater efficacy for weight loss and fat metabolism than semaglutide. Average weight loss with tirzepatide is up to 22.5% of body weight in 72 weeks.
Semaglutide (injectable and oral disintegrating tablets)
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps increase insulin sensitivity, decrease glucagon production, delay gastric emptying, and increase fat metabolism, resulting in weight loss. Average weight loss with semaglutide is up to 14.9% of body weight in 72 weeks.
Tirzepatide (injectable and oral disintegrating tablets)
Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The combined action of these hormones provides greater efficacy for weight loss and fat metabolism than semaglutide. Average weight loss with tirzepatide is up to 22.5% of body weight in 72 weeks.
Semaglutide (injectable and oral disintegrating tablets)
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps increase insulin sensitivity, decrease glucagon production, delay gastric emptying, and increase fat metabolism, resulting in weight loss. Average weight loss with semaglutide is up to 14.9% of body weight in 72 weeks.